Related Experiment Videos
Advanced uterine sarcoma; response to chemotherapy.
1Dept. of Gynecologic Oncology, Roswell Park Memorial Institute, Buffalo, New York.
European Journal of Gynaecological Oncology
|January 1, 1988
Summary
Chemotherapy for advanced uterine sarcoma showed limited response to single agents. Combination regimens like CYVADIC, cisplatin/dacarbazine, and VAC offered better outcomes, but more effective treatments are needed.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Cancer Therapeutics
Background:
- Uterine sarcoma is a rare and aggressive gynecologic malignancy.
- Effective chemotherapy regimens for advanced disease remain a challenge.
- Previous studies have evaluated various treatment strategies with varying success.
Purpose of the Study:
- To retrospectively analyze the efficacy of multiple chemotherapy regimens in advanced uterine sarcoma.
- To identify active single agents and combination therapies.
- To assess treatment response across different uterine sarcoma histologies.
Main Methods:
- Retrospective analysis of 78 evaluable patients with advanced uterine sarcoma treated over 15 years.
- Evaluation of response rates for single-agent chemotherapy (doxorubicin, methotrexate, cisplatin).
- Assessment of response rates for combination regimens including CYVADIC, cisplatin/dacarbazine, and VAC.
Main Results:
- Single agents showed low response rates (5-11%).
- Combination regimens demonstrated higher efficacy: CYVADIC (23%), cisplatin/dacarbazine (21%), and VAC (18%).
- No significant difference in response rates was observed across different uterine sarcoma histologies.
Conclusions:
- Combination chemotherapy offers improved response rates compared to single agents for advanced uterine sarcoma.
- Current regimens provide modest benefits, highlighting the need for novel therapeutic approaches.
- Further research into more active agents and combinations is crucial for improving patient outcomes.